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Background: Pancreatic cancer is frequently resistant to cancer therapeutics. Smoking and alcoholism are risk
factors and pancreatic cancer patients often undergo nicotine replacement therapy (NRT) and treatment for alcohol
dependence. Based on our report that low dose nicotine within the range of NRT causes gemcitabine resistance in
pancreatic cancer, our current study has tested the hypothesis that GABA or the selective GABA-B-R agonist
baclofen used to treat alcohol dependence reverse nicotine-induced gemcitabine resistance in pancreatic cancer.
Methods: Using mouse xenografts from the gemcitabine–sensitive pancreatic cancer cell line BXPC-3, we tested
the effects of GABA and baclofen on nicotine-induced gemcitabine resistance. The levels of cAMP, p-SRC, p-ERK,
p-AKT, p-CREB and cleaved caspase-3 in xenograft tissues were determined by ELISA assays. Expression of the two
GABA-B receptors, metalloproteinase-2 and 9 and EGR-1 in xenograft tissues was monitored by Western blotting.
Mechanistic studies were conducted in vitro, using cell lines BXPC-3 and PANC-1 and included analyses of
cAMP production by ELISA assay and Western blots to determine protein expression of GABA-B receptors,
metalloproteinase-2 and 9 and EGR-1.
Results: Our data show that GABA was as effective as gemcitabine and significantly reversed gemcitabine resistance
induced by low dose nicotine in xenografts whereas baclofen did not. These effects of GABA were accompanied by
decreases in cAMP, p-CREB, p-AKT, p-Src, p-ERK metalloproteinases-9 and −2 and EGR-1 and increases in cleaved
caspase-3 in xenografts whereas baclofen had the opposite effects. In vitro exposure of cells to single doses or seven
days of nicotine induced the protein expression of MMP-2, MMP-9 and EGR-1 and these responses were blocked by
GABA. Baclofen downregulated the protein expression of GABA-B-Rs in xenograft tissues and in cells exposed to
baclofen for seven days in vitro. This response was accompanied by inversed baclofen effects from inhibition of
cAMP formation after single dose exposures to stimulation of cAMP formation in cells pretreated for seven days.
Conclusions: These findings suggest GABA as a promising single agent for the therapy of pancreatic cancer and
to overcome nicotine-induced gemcitabine resistance whereas treatment with baclofen may increase
gemcitabine resistance.Background
Pancreatic cancer has a mortality > 90% within one year
of diagnosis due to a lack of clinical symptoms during
early stage disease and poor responsiveness to current
cancer therapeutics [1]. Smoking is a well documented risk
factor for this malignancy [2] and nicotine replacement* Correspondence: hmsch@utk.edu
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unless otherwise stated.therapy (NRT) frequently accompanies chemotherapy. Al-
coholism also increases the risk for pancreatic cancer [3].
The synthetic selective GABA-B-receptor (GABA-B-R)
agonist baclofen has been recommended for the treatment
of addiction by drug abuse, including nicotine and alcohol
[4,5]. Pancreatic cancer patients may thus simultaneously
be exposed to baclofen and chemotherapeutics. On the
other hand, GABA is an agonist for all GABA receptors
(GABA-A and GABA-B receptors) and has been used as a
nutritional supplement for many years due to its calming
and anxiolytic effects [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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comparable to the blood nicotine levels in heavy smokers
accelerated the progression of pancreatic cancer xeno-
grafts by increasing cell proliferation and that treatment of
the mice with GABA in the drinking water blocked this
effect via GABA-B-receptor (GABA-B-R)-mediated inhib-
ition of cAMP-dependent pathways [7,8]. In accord with
these findings, single dose exposures of pancreatic cancer
cells in vitro to GABA or baclofen also inhibited via this
mechanism cell proliferation and migration induced by
the beta-adrenergic receptor agonist isoproterenol [9].
GABA additionally inhibited alcohol-induced cell prolifer-
ation and migration via reduction of cAMP formation [8].
More recently, we have shown that low dose nicotine
in the range of systemic nicotine levels in moderate
smokers and individuals undergoing NRT failed to
increase cell proliferation-mediated pancreatic cancer
xenograft progression but instead induced gemcitabine
resistance by modulating apoptotic pathways [10].
Gemcitabine (Gemzar) is the leading therapeutic for
pancreatic cancer, albeit with poor success [1,11]. Gemci-
tabine exerts cytotoxic and apoptotic effects by inhibiting
ribonucleotide reductase and DNA polymerization [12].
Gemcitabine resistance frequently develops and recent
findings suggest that agents that reduce p-ERK expression
may help to overcome this problem [13]. Having shown
that GABA and baclofen each inhibit p-ERK when admin-
istered as a single dose to pancreatic cancer cells in vitro
by reducing the formation of cAMP [9], our current
experiments have tested the hypothesis that both agents
reverse gemcitabine resistance induced by low dose
nicotine in pancreatic cancer.
Methods
Cell lines
The human pancreatic ductal adenocarcinoma cell lines
PANC-1 and BXPC-3 were purchased from the American
Type Culture Collection (Manassas, VA) and maintained
in an atmosphere of 5% CO2 at 37°C in the culture
medium recommended by the vendor. PANC-1 harbors
an activating point mutation in codon 12 of the k-ras gene
whereas BXPC-3 does not have ras mutations. The human
PDAC cell line BXPC-3 is relatively responsive to gemcita-
bine whereas PANC-1 cells are relatively resistant [13].
We therefore conducted the xenograft studies in mice
with BXPC-3 only while the in vitro experiments were
conducted with both cell lines. Both cell lines were
authenticated in June 2013 by species-specific PCR
evaluation (Research Animal Diagnostic Laboratory,
Columbia, MO, USA). Complete medium for PANC-1
was comprised of DMEM medium supplemented with
10% fetal bovine serum (FBS) and for BXPC-3 cells
RPMI 1640 medium supplemented with 10% FBS. No
antibiotics were used during maintenance of cells andin vitro experiments because antibiotics significantly
alter the proteome of cells, leading to potentially aberrant
signaling responses [14].
Chemicals, reagents and antibodies
Gemcitabine (Gemzar hydrochloride) was purchased from
Eli Lilly (Indianapolis, IN, USA). Baclofen, GABA and
nicotine ((−)-Nicotine hydrogen tartrate) were purchased
from Sigma Aldrich (St. Louis, MO, USA). Antibodies
against the following proteins were purchased from
Abcam (Cambridge, MA, USA): GABA-B receptor
1, GABA-B-receptor 2, beta-actin, metalloproteinase-2
(MMP-2), metalloproteinase-9 (MMP-9) and early growth
response gene 1 (EGR-1). ELISA assay kits for the quan-
titative determination of intracellular cyclic adenosine
monophosphate (cAMP) were purchased at Enzo Life
Sciences (Farmingdale, NY, USA). ELISA assay kits for
the quantitative determination of the phosphorylated
signaling proteins extra cellular signal regulated kinase
(ERK), cAMP response element binding protein (CREB),
v-akt murine thymoma viral oncogene homolog (AKT),
for Caspase-3 and for v-src avian sarcoma viral oncogene
homolog (Src) were purchased at Invitrogen (Carlsbad,
CA, USA) and MBL International Corporation (Woburn,
MA, USA), respectively.
Animal experiment
The animal experiment was approved by the University
of Tennessee Knoxville Institutional Animal Care and Use
Committee (IACUC). Male, 6-week-old athymic nude
mice (Harlan Sprague Dawley Inc., Frederick, MD, USA)
were housed in our laboratory animal facility under stand-
ard laboratory conditions with free access to food (auto-
claved Purina rodent chow) and autoclaved water. All
animals were subcutaneously inoculated in the flank
region with BXPC-3 cells (3 × 106 in 0.2 mL of PBS,
viability > 95%). The mice were randomly assigned to
the following treatment groups (n = 10): 1) untreated
control, 2) Gemzar (Eli Lilly) twice a week intra-
peritoneally (50 mg/kg), 3) Gemzar + nicotine (1 μM/L) in
the drinking water with changes of water bottles twice/
week, 4) GABA (10 mg/kg, 5 days a week by intra-
peritoneal injection), 5) GABA+Gemzar, 6) Nicotine +
GABA+Gemzar, 7) baclofen (1 mg/kg by intraperitoneal
injection 5 days/week, 8) Nicotine + gemzar + baclofen.
The dose of nicotine used is within the range of plasma
nicotine levels in moderate smokers [15] or patients
undergoing NRT [16]. The dose of GABA is within the
daily dose recommended for natural GABA supplementa-
tion [6]. The dose of baclofen is within the dose recom-
mended for the treatment of alcohol dependence [4].
Regulations by the University of Tennessee Knoxville
Animal Care and Use Committee mandated that the
mice be sacrificed as soon as xenografts had reached a
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reach that diameter within 4 weeks after subcutaneous
injection, we had to start all treatments one day after
injection of cancer cells in order to ensure a 4-week
duration of treatments. Modulation of survival times by
treatments could thus not be investigated because xeno-
grafts in the untreated control group reached that diameter
4 weeks after tumor cell inoculation and all animals were
euthanized at that time to allow for comparisons among
all treatment groups and controls of mechanistic data col-
lected from xenograft tissues at an identical time point.
Treatment started 1 day after subcutaneous implantation
of the tumor cells. All animals were observed for 30 days
after inoculation with cancer cells, while being monitored
daily by a staff veterinarian board certified in Laboratory
Animal Science. Body weights were recorded weekly.
Water consumption was monitored by measuring the
tap water with and without the nicotine in and out
twice/week. Two perpendicular diameters (length and
width) of each xenograft were measured with a caliper
weekly, and tumor volumes were calculated as follows:
(length/2) × (width2). At the end of the 30-day observation
period, the animals were euthanized by CO2 inhalation.
The tumors were excised and snap frozen in liquid nitro-
gen and stored at −80°C until analysis.
ELISA assays
The expression of signaling proteins was determined by
commercially available assay kits when such kits were
available to allow for quantitative analyses of the data. In
addition, cAMP levels were determined by ELISA assays.
All ELISA assays were conducted following the instruc-
tions of the vendor and using an Epoch Micro plate
Spectrophotometer (BioTek, Winooski, VT). Primary
absorbance was read at 405 nm for cAMP and at
450 nm for p-ERK at threonine 202 and tyrosine 204, p-
CREB at serine 133, p-AKT at serine 473, p-Src (630 nm
reference wavelength), and at primary496 nm for cleaved
caspase-3 (520 reference wavelength). All ELISA assays
were conducted with 5 samples per treatment group.
Western blots
Western blots in triplicate were used to determine the
expression of proteins for which quantitative ELISA
assays were not available. The protein expression of
the metalloproteinases MMP-2 and MMP-9, the early
growth response gene 1 (EGR-1) in xenograft tissues
was thus monitored by quantitative densitometry of
the western blots using previously published proce-
dures [17].
In vitro experiments
To obtain mechanistic insight into the observed differen-
tial effects of baclofen and GABA on xenograft growth inmice, in-vitro experiments with PANC-1 and BXPC-3
cells were conducted.
Effects of chronic GABA and baclofen on GABA-B-R protein
Cells were seeded into 6-well plates (n = 5) at a density
of 50,000 cells per well. Each of the cell lines was treated
for 7 days with 10 μM, 30 μM and 50 μM of baclofen or
GABA with daily replacement of drugs. Protein was
isolated using standard protocol. Protein concentra-
tions were determined using the BCA Protein Assay
(Pierce, Rockford, IL) and Western blots were performed
as previously described [10,17].
Effects of chronic baclofen on cAMP production
PANC-1 and BXPC-3 cell lines were seeded in 6-well
plates at a density of 50,000 cells per well and grown in
complete media (DMEM and RPMI respectively supple-
mented with 10% FBS). Chronic treatments with 50 μM
baclofen were started on the following day and contin-
ued for 7 days with daily replenishment of drug. On day
7 the cells were switched to their respective basal media
and serum starved for 24 hours. The cells were then
washed with PBS and fresh basal media was added.
Following exposure for 30 minutes to IBMX (1 mM) to
prevent the enzymatic dissociation of intracellular
cAMP, cells were first treated with baclofen (concen-
trations ranging from 1nM to 100 μM) for 4 hrs and
then treated with 1 μM Isoproterenol for 30 min. Iden-
tical assay conditions were used in cells not pretreated
with baclofen. Cells neither exposed to baclofen nor to
isoproterenol served as negative controls. Cells not
pretreated with baclofen and treated with isoproterenol
alone for 30 minutes served as positive controls. Proteins
were isolated using the manufacturer’s recommendation
for the cAMP assay. Quantitative analyses of the samples
(n = 5) were conducted using a cAMP ELISA kit (Enzo
Life Sciences).
Effects of nicotine and GABA on metalloproteinases and
EGR-1
PANC-1 and BXPC-3 cells were seeded in 100 mm
plates at a density of 200,000-300,000 cells per plate with
5 wells per treatment group (n = 5). To assess the effects
of single dose exposures, cells were allowed to attach to
the well surface for 24 hours and were then exposed for
4 hours to GABA (50 μM), nicotine (1 μM) or the
combination of both agents. To determine the effects of
chronic treatments, cells were exposed to identical
concentrations of GABA, nicotine, or the combination
of both for 7 days, with daily changes in culture medium
containing these agents. Cells were lysed and protein
expressions analyzed by triplicate Western blotting as
previously described [10,18]. Protein bands were then
visualized with enhanced chemiluminescence reagent
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Quantitative densitometry was conducted from triplicate
Western blots as previously described [17,18].
Statistical evaluation of data
Using GraphPad Instat 3 software (GraphPad Instant
Biostatistics), the Kolmogorov and Smirnov test estab-
lished that the data did not follow a Gaussian distribution
and were therefore analyzed by the non-parametric




Changes in xenograft growth
The variation among xenograft volume medians of all
treatment groups was significantly greater than expected
by chance in weeks 2, 3 and 4 of the mouse experiment
Figure 1A and 1B). In accord with our previous report
[10], nicotine significantly increased resistance to gemci-
tabine in weeks 2–4 of the experiment (Figure 1A). This
response was significantly reversed by simultaneous
treatment of the mice with GABA (Figure 1A). By contrast,
baclofen failed to significantly reduce nicotine-induced
gemcitabine resistance (Figure 1B). GABA and gemcitabine
cooperatively reduced xenograft volumes and GABA
treatment alone was as effective as gemcitabine treatment
alone (Figure 1A). By contrast, the gemcitabine-induced
reduction in xenograft volumes was significantly dimin-
ished by baclofen in weeks 2 and 4 (Figure 1B), suggesting
an increase in gemcitabine resistance. Moreover, treat-
ment with baclofen alone did not significantly reduce
xenograft volumes (Figure 1B).
Modulation of cAMP levels in xenograft tissues
The activation of adenylyl cyclase by Gs-coupled receptors
such as the β-ARs is the single rate-limiting step required
for the intracellular formation of cyclic adenosine mono-
phophate (cAMP). Treatment of mice with gemcitabine
alone or GABA alone were equally effective in reducing
cAMP production in tumor tissues whereas baclofen
alone failed to inhibit cAMP formation (Figure 2A).
Simultaneous treatment of the mice with gemcitabine and
nicotine significantly increased cAMP levels over those
observed with gemcitabine alone (Figure 2A), an effect
that was reversed by GABA but not baclofen (Figure 2A).
Changes of p-CREB levels in xenograft tissues
The transcription factor cAMP response element bind-
ing protein (CREB) is a downstream effector of cAMP
that is phosphorylated by cAMP-activated protein kinase
A (PKA). Gemcitabine alone significantly inhibited the
phosphorylation of CREB in xenograft tissues, a response
further enhanced by simultaneous treatment with GABA(Figure 2B) but not by baclofen. Nicotine completely
abrogated the gemcitabine-induced reduction in p-CREB
an effect significantly reversed by GABA but not baclofen
(Figure 2B). GABA alone significantly decreased the levels
of p-CREB whereas baclofen alone even increased p-CREB
levels above control levels.
Changes in the levels of cleaved caspase-3 in xenograft
tissues
Caspase-3 is cleaved to initiate apoptosis, a mechanism
activated by numerous cancer therapeutics, including
gemcitabine. In accord with our previous report, and the
documented apoptotic effects of gemcitabine [19], xeno-
graft tissues in gemcitabine treated mice demonstrated
more than three-fold higher levels of cleaved caspase-3
than in control animals and simultaneous treatment of
the animals with nicotine significantly reduced this
response (Figure 3A). GABA completely reversed this
adverse effect of nicotine whereas baclofen did not.
Treatment with GABA alone significantly increased
cleaved caspase-3 over the levels observed in controls
(Figure 3A). Baclofen alone did not significantly alter
cleaved caspase-3 levels in comparison with controls
but significantly reduced gemcitabine-induced induction
of caspase-3 (Figure 3A).
Modulation of p-AKT levels in xenograft tissues
The signaling protein AKT is involved in the regulation of
cell proliferation and apoptosis, is activated downstream
of β-ARs in pancreatic cancer cells in a cAMP-dependent
manner, and AKT inhibitors are being used in combin-
ation with cancer therapeutics to improve clinical out-
comes in pancreatic cancer patients. Treatment with
gemcitabine or GABA alone significantly reduced the
levels of p-AKT in xenograft tissues whereas baclofen
alone significantly induced p-AKT (Figure 3B). Simultan-
eous treatment of the mice with gemcitabine and nicotine
completely abrogated the inhibitory effects of gemcitabine
on p-AKT. This adverse effect of nicotine was significantly
reduced in animals receiving GABA (Figure 3B).
Modulation of p-Src levels in xenograft tissues
The signaling protein Src participates in the regulation
of cell proliferation, is activated in pancreatic cancer cells
in a cAMP-dependent manner, and is among the
molecular targets currently utilized for the therapy of
pancreatic cancer. Gemcitabine alone and GABA alone
each significantly reduced p-Src in xenograft tissues
(Figure 4A) and the combination treatment with both
agents further enhanced this effect. By contrast, baclofen
alone or in the presence of gemcitabine significantly
induced p-Src above the levels observed in controls
(Figure 4A) and was as effective as nicotine in abro-
gating the inhibitory effects of gemcitabine on Src
Figure 1 A: Xenograft volumes. From week 2 through 4 variations in xenograft volumes among treatment groups were significant (p < 0.0001
by Kruskal Wallis ANOVA). Gemcitabine (Gem) treatment significantly (p < 0.001 by Mann–Whitney test) reduced xenograft volumes in weeks 2
through 4 as compared with xenografts in untreated control mice. Simultaneous exposure of the animals to nicotine (Nic) in the drinking water
significantly (p < 0.005 by Mann–Whitney test) reduced this effect of gemcitabine in weeks 2 and 3. Gaba (G) reversed this adverse effect of
nicotine (p < 0.0005 by Mann–Whitney test) and reduced xenograft volumes below the sizes observed in animals treated with gemcitabine alone.
GABA treatment alone was as effective as gemcitabine in reducing xenograft sizes. B: Xenograft volumes. From week 2 through 4 variations in
xenograft volumes among treatment groups were significant (p < 0.001 by Kruskal Wallis ANOVA). Baclofen failed to reverse nicotine-induced
gemcitabine resistance and did not significantly reduce xenograft volumes when administered as a single agent. Data points in graphs A and B
are mean values and standard errors of xenograft volumes from 10 mice per treatment group.
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adverse effect of nicotine (Figure 4A).
Changes in p-ERK levels of xenograft tissues
The signaling proteins ERK1/2 are involved in the regula-
tion of cell proliferation. They are activated in pancreatic
cancer cells downstream of the epidermal growth factor
receptor (EGFR), which is activated by cAMP-dependent
transactivation of the receptor itself and by cAMP-
induced production of EGF. Gemcitabine and GABA
each significantly reduced the levels of p-ERK in xeno-
graft tissues when given as single agent treatments and
this effect was significantly enhanced when these
agents were given in combination (Figure 4B). Nicotinecompletely abrogated gemcitabine-induce p-ERK inhibition,
increasing p-ERK levels significantly above the levels ob-
served in controls and this effect was significantly reduced
by GABA (Figure 4B). By contrast, baclofen significantly
increased the levels of p-ERK in the presence and absence
of gemcitabine (Figure 4B).
Modulation in the protein expression of MMP-9, MMP-2
and EGR-1 of xenograft tissues
The metalloproteinases MMP-2 and MMP-9 are involved
in the regulation of cancer cell migration and metastasis,
while the transcription factor EGR-1 participates in the
regulation of cell proliferation, migration and apoptosis.
Treatment with gemcitabine significantly reduced the
Figure 3 A: Levels of cleaved caspase-3 in xenograft tissues.
Cleaved caspase-3 was measured in xenograft tissues by ELISA assay.
The differences among treatment groups were significant (P < 0.001
by Kruskal-Wallis ANOVA). Gemcitabine significantly increased cleaved
caspase-3 levels, a response enhanced by GABA but significantly reduced
by baclofen or nicotine. GABA restored these anti-apoptotic effects of
gemcitabine in nicotine treated mice while also significantly increasing
cleaved caspase-3 levels when given as a single agent. Baclofen
significantly reduced the apoptosis-inducing effect of gemcitabine
while failing to reverse the adverse effects of nicotine. *Significantly
( p < 0.01 by Mann–Whitney test) different from controls.✖Significantly
(p < 0.01 by Mann–Whitney test) different from gemcitabine alone.
★
★
Significantly (p < 0.01 by Mann–Whitney test) different from treatment
with gemcitabine plus nicotine. B: Levels of p-AKT in xenograft tissues
(ELISA assays). Variation in p-AKT levels among treatment groups was
significant (p < 0.001 by Krsukal-Wallis ANOVA). Gemcitabine and GABA
each significantly reduced p-AKT levels whereas baclofen significantly
increased p-AKT levels above those observed in control mice. Nicotine
and baclofen each significantly diminished the inhibitory effects of
gemcitabine on p-AKT. All data are mean values and standard
deviations from five randomly selected xenografts per treatment
group. ★Significantly ( p < 0.01 by Mann–Whitney test) different
from controls. ✖Significantly (p < 0.01 by Mann–Whitney test)
different from gemcitabine alone.
★
★
Significantly (p < 0.01 by
Mann–Whitney test) different from treatment with gemcitabine
plus nicotine.
Figure 2 A: Levels of cAMP in xenograft tissues. (ELISA assays).
Gemcitabine and GABA were equally effective in significantly
reducing cAMP levels. Nicotine significantly reduced this effect of
gemcitabine, a response reversed by simultaneous treatment with
GABA. Baclofen alone significantly increased cAMP levels, diminished
the effects of gemcitabine and enhanced the adverse effects of
nicotine in gemcitabine treated animals. The differences among
treatment groups were significant (P < 0.001 by Kruskal-Wallis
ANOVA). Data are mean values and standard deviations of five
randomly selected xenografts per treatment group. ★Significantly
( p < 0.01 by Mann–Whitney test) different from controls. ✖Significantly
(p < 0.01 by Mann–Whitney test) different from gemcitabine alone.
★
★
Significantly (p < 0.01 by Mann–Whitney test) different from
treatment with gemcitabine plus nicotine. The inset shows representative
Western blots from xenografts exemplifying downregulated receptor
proteins of both GABA-B-Rs in the mice treated with baclofen alone
while receptor proteins remained unchanged in the xenograft of mice
treated with GABA alone. B: Levels of p-CREB in xenograft tissues. ELISA
assays were used to determine the levels of p-CREB in xenograft tissues.
The differences among treatment groups were significant (P < 0.0001 by
Kruskal-Wallis ANOVA). Gemcitabine and GABA each significantly reduced
p-CREB levels, an effect significantly enhanced by the combination of
both agents. Nicotine completely blocked this anti-tumorigenic effect of
gemcitabine, an effect reversed by GABA. Baclofen had adverse effects
similar to nicotine on gemcitabine-induced p-CREB reduction while even
significantly increasing p-CREB levels over those observed in controls
when given as a single agent. Data are mean values and standard
deviations of five randomly selected xenografts per treatment
group. ★Significantly ( p < 0.01 by Mann–Whitney test) different




Significantly (p < 0.01 by Mann–Whitney
test) different from treatment with gemcitabine plus nicotine.
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Figure 4 A: Levels of p-Src in xenograft tissues (ELISA assay).
Variations of p-Src among treatment groups were significant (p < 0.001
by Kruskal-Wallis ANOVA). Gemcitabine and GABA alone and in
combination significantly reduced the levels of both phosphorylated
signaling proteins whereas baclofen significantly increased their levels.
Baclofen and nicotine each significantly reduced the inhibitory effects
of gemcitabine on both proteins. GABA significantly restored the
effects of gemcitabine in the presence of nicotine. All data are mean
values and standard deviations of five randomly selected xenografts
per treatment group. ★Significantly ( p < 0.01 by Mann–Whitney test)
different from controls. ✖Significantly (p < 0.01 by Mann–Whitney test)
different from gemcitabine alone.
★
★
Significantly (p < 0.01 by
Mann–Whitney test) different from treatment with gemcitabine
plus nicotine. B: Levels of p-ERK in xenograft tissues (ELISA assays).
Differences among treatment groups were significant (p < 0.0001
by Kruskal-Wallis ANOVA). Treatment-induced changes in p-ERK
were similar to those of p-Src. Data are mean values and standard
deviations of five randomly selected xenografts per treatment
group. ★Significantly ( p < 0.01 by Mann–Whitney test) different
from controls. ✖Significantly (p < 0.01 by Mann–Whitney test)
different from gemcitabine alone.
★
★
Significantly (p < 0.01 by
Mann–Whitney test) different from treatment with gemcitabine
plus nicotine.
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tissues while the protein expression of MMP-9 did not
change significantly (Figure 5A, 5B). Nicotine signifi-
cantly induced the expression of both metalloprotein-
ases and EGR-1 above the levels of controls when
administered simultaneously with gemcitabine while
also significantly reversing the gemcitabine-induced
inhibition of EGR-1 expression (Figure 5A, 5B). GABA
reversed these effects of nicotine and GABA treatment
alone reduced both metalloproteinases below controlFigure 5 A: Western blots from xenograft tissues. Changes in
the protein expression of metalloproteinases MMP-9 and MMP-2 and
of the transcription factor EGR-1 in xenograft tissues of the six
treatment groups. B: Densitometry data of proteins exemplified in
Figure 5A. Quantitative densitometry data were generated from
triplicate western blots for the determination of MMP-9, MMP-2 and
EGR-1in xenograft tissues. The differences among treatment groups
were significant (p < 0.001 by Kruskal-Wallis ANOVA). Gemcitabine
treatment alone reduced the protein expression of MMP-2 and
EGR-1. Simultaneous treatment with nicotine abrogated these responses
and additionally increased MMP-9 expression above control levels. GABA
showed strong inhibiting effects on all three proteins as a single agent
and in combination with gemcitabine. ★Significantly ( p < 0.01 by
Mann–Whitney test) different from controls. ✖Significantly (p < 0.01 by




( < 0.01 by Mann–Whitney test) different from treatment with
gemcitabine plus nicotine.
Figure 6 A: Intracellular cAMP in vitro in PANC-1 cells (ELISA
assay). The differences among treatment groups were significant (p
< 0.0001 by Kruskal-Wallis ANOVA). Exposure of unpretreated cells to
the selective beta-adrenergic receptor agonist isoproterenol (1 μM)
significantly increased cAMP levels. This response was significantly
inhibited by the selective GABA-B-R agonist baclofen, with increasing
concentrations yielding lesser inhibition. By contrast, none of the
baclofen concentrations tested inhibited cAMP stimulation by iso-
proterenol in cells pretreated for seven days with baclofen (50 μM)
and baclofen even significantly increased cAMP levels above those
observed with isoproterenol alone. ★Significantly ( p < 0.01 by
Mann–Whitney test) different from controls.
★
★
Significantly ( < 0.01
by Mann–Whitney test) different from cells pretreated for 7 days
with baclofen. Data are mean values and standard deviations of five
samples per treatment group. Identical assays conducted with BXPC-
3 cells yielded similar results (data not shown). B: Western blots of
GABA-B receptors in pancreatic cancer cell lines in vitro. The protein
expression of the two GABA-B receptors decreased in response to
ascending concentrations of chronic (7 days) baclofen in BXPC-3
and PANC-1 cell in vitro. C: Western blots of GABA-B receptors in
BXPC-3 and PANC-1 cells in vitro. The protein expression of the two
GABA-B receptors in response to ascending concentrations of
chronic (7 days) GABA remained unchanged in BXPC-3 and PANC-1
cell in vitro.
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having little effects on MMP-9 or EGR-1.
In vitro studies
Modulation of the function and expression of GABA-B
receptors by chronic baclofen
The two GABA-B receptors (GABA-B-R1, GABA-B-R2)
are coupled to the inhibitory G-protein Gi that reduces
the formation of cAMP by inhibiting the activation of
adenylyl cyclase by receptors such as the β-ARs, that are
coupled to the stimulatory G-protein Gs [9]. The
proliferation and migration of pancreatic cancer cells
is stimulated by agonists for the Gs-coupled beta-
adrenergic receptors and nicotine triggers this response
by stimulating the production of their physiological ago-
nists norepinephrine and epinephrine in pancreatic cancer
cells [9,20]. The failure of the selective GABA-B-R agonist
baclofen to inhibit xenograft growth in the mouse experi-
ment suggested to us that chronic treatment with baclofen
might have desensitized the GABA-B-Rs. This hypothesis
is supported by cAMP assays conducted in BXPC-3
and PANC-1 cells in vitro and exemplified in Figure 6A.
The selective beta-adrenergic agonist isoproterenol signifi-
cantly increased intracellular cAMP levels and this
response was reduced by single doses of baclofen at
concentrations from 1 nM through 10 μM. There was an
inverse dose–response relationship, with increasing con-
centrations being less inhibitory and no inhibition detect-
able at the highest dose of 100 μM baclofen (Figure 6A), a
finding consistent with receptor desensitization by high
agonist concentrations. Pretreatment of the cells for 7 days
with 50 μM baclofen resulted in a complete reversal of
GABA-B-R function as evidenced by significant stimula-
tion of cAMP formation in response to each single baclo-
fen concentration tested even above the levels observed
with isoproterenol (Figure 6A). These findings are in
accord with the results of Western blots that revealed
downregulated protein expression of both GABA-B-Rs
in BXPC-3 and PANC-1 cells exposed for 7 days to
50 μM baclofen (Figure 6B). By contrast, identical
treatment of both cell lines with GABA, which was
highly effective in inhibiting xenograft growth, did not
change the protein expression of these receptors
(Figure 6C).
Effects of single dose and chronic nicotine and GABA on
metalloproteinases and EGR-1 in vitro
Western blots of xenograft tissues suggested that chronic
nicotine induced while GABA inhibited MMP-9, MMP-2
and EGR-1 in pancreatic cancer. We therefore treated cell
lines BXPC-3 and PANC-1 in vitro with a single dose or
for 7 days with nicotine (1 μM), GABA (50 μM) or the
combination of both agents and assessed the protein
expression of these three targets by Western blots. AsFigures 7A-C and 8A-C show, acute as well as chronic
exposure to nicotine significantly induced the protein
expression of both metalloproteinases and EGR-1 in
both cell lines, responses significantly reduced by sim-
ultaneous exposure to GABA. Moreover, GABA alone
Figure 7 A: Western blots of signaling proteins in BXPC-3 cells
in vitro. Changes in the protein expression of the metalloproteinases
MMP-2 and MMP-9 and on the transcription factor EGR-1 exposure to
single doses or 7 days of GABA (50 μM) , nicotine (1 μM) or the
combination of both agents in BXPC-3 cells in vitro. B: Densitometry
data of signaling proteins in BXPC-3 cells treated for 7 days. Quantitative
densitometry was conducted from triplicate western blots of BXPC-3 cells
after 7 days of treatment. The differences among treatment groups for
MMP-2, MMP-9 and EGR-1 were significant (p < 0.0001 by Kruskal-Wallis
ANOVA). Nicotine induced the expression of these three proteins while
GABA had strong inhibiting effects in the absence and presence of




Significantly ( < 0.005 by Mann–Whitney test) different from
treatment with nicotine. C: Densitometry data of signaling proteins in
BXPC-3 cells after single dose treatments. Quantitative densitometry was
conducted from triplicate western blots of BXPC-3 cells after single dose
treatments treatment. The differences among treatment groups for
MMP-2, MMP-9 and EGR-1 were significant (p < 0.0001 by Kruskal-Wallis
ANOVA). Nicotine induced the expression of these three proteins while
GABA had strong inhibiting effects in the absence and presence of




Significantly ( < 0.005 by Mann–Whitney test) different from
treatment with nicotine.
Figure 8 A: Western blots of signaling proteins in PANC-1 cells
in vitro. Exposure to single doses or 7 days of GABA (50 μM),
nicotine (1 μM) or the combination of both agents modulated the
protein expression of the metalloproteinases MMP-2 and MMP-9 and
on the transcription factor EGR-1 in PANC-1 cells in vitro. B:
Densitometry data from PANC-1 cells treated for 7 days. Quantitative
densitometry was generated from triplicate western blots of PANC-1
cells after 7 days of treatment. The differences among treatment
groups for MMP-2, MMP-9 and EGR-1 were significant (p < 0.0001 by
Kruskal-Wallis ANOVA). Nicotine induced the expression of these
three proteins while GABA had strong inhibiting effects in the
absence and presence of nicotine. ★Significantly ( p < 0.005 by
Mann–Whitney test) different from controls.
★
★
Significantly ( < 0.005
by Mann–Whitney test) different from treatment with nicotine. C:
Quantitative densitometry data after single dose treatments of PANC-1
cells. The differences among treatment groups for MMP-2, MMP-9 and
EGR-1 were significant (p < 0.0001 by Kruskal-Wallis ANOVA). Nicotine
induced the expression of these three proteins while GABA had strong
inhibiting effects in the absence and presence of nicotine. ★Significantly
( p < 0.005 by Mann–Whitney test) different from controls.
★
★
Significantly ( < 0.005 by Mann–Whitney test) different from
treatment with nicotine.
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significantly below control levels, an effect particularly
prominent after 7 days of exposure.
Discussion
Our experimental in vivo and in vitro data show, for the
first time, that GABA effectively reversed nicotine-
induced gemcitabine resistance of pancreatic cancer.
Moreover, our findings suggest that single agent therapy
with GABA is as effective as gemcitabine in pancreatic
cancer. The observed nicotine-induced changes in p-ERK,
p-Src, p-CREB, p-AKT and caspase-3 in xenograft tissues
and in vitro are in accord with reports describing
mechanisms of nicotine-induced pancreatic cancer cell
proliferation [18], inhibition of apoptosis [10,21] and
increase in gemcitabine resistance [21,22]. The inhibi-
tory effects of GABA on these targets confirm earlier
reports that the activation of ERK, Src and CREB in
pancreatic cancer cells is cAMP-dependent and reduced
by activation of the Gi-coupled GABA-B receptors [9].
While gemcitabine is primarily known for its cytotoxic
and pro-apoptotic effects, it has also been shown to act as
an analgesic that decreased cAMP by reducing the deg-
radation of Gi [23]. The gemcitabine-induced reductions
in cAMP. P-CREB, p-ERK, p-Src and p-AKT are in accord
with these findings. Our in vitro and in vivo findings that
nicotine induced metalloproteinases 9 and 2 are in accord
with analyses by PCR and immunohistochemistry that
revealed increases in MMP-9 associated with induction
of vascular endothelial growth factor in pancreatic can-
cer cells exposed in vitro to nicotine [24]. Collectively,
these findings are of immediate translational relevance
and warrant clinical trials with GABA alone and as a
tool to overcome nicotine-induced gemcitabine resistance
in pancreatic cancer patients.
Effects of nicotine on the EGR-1 gene in pancreatic
cancer cells has not been studied to date. The transcription
factor EGR-1participates in the regulation of cell prolifera-
tion, differentiation and apoptosis and can act as a tumor
promoter or tumor suppressor pending on the type of
cancer under study and the experimental conditions used
[25-29]. Our current in vivo and in vitro findings are in
accord with observations that nicotine induced EGR-1
expression in pheochromocyatoma cells [30] and that
EGR-1 is involved in the conversion of norepinephrine
to epinephrine by the enzyme phenylethanolamine N-
methyltransferase [31]. We have recently shown that
nicotine induces the synthesis and release of norepineph-
rine and epinephrine from pancreatic cancer cells with
both neurotransmitters acting as autocrine growth factors
via cAMP-dependent signaling cascades that were inhib-
ited by GABA [17,18]. The observed modulation of EGR-
1 expression in the current experiments are thus likely
associated with changes in the activity of these pathways.Similar to many classic cancer therapeutics, gemcitabine
is a synthetic agent that induces apoptosis and cytotoxicity
not only in cancer cells but also in normal epithelial cells,
resulting in adverse side effects [11,13,32]. By contrast,
GABA is a physiological product of the mammalian or-
ganism that serves as the major inhibitory neurotrans-
mitter in the nervous system [33]. GABA also restores
cAMP homeostasis via inhibition of adenylyl cyclase
activation by the Gi-coupled GABA-B-Rs when Gs-coupled
receptors cause excessive cAMP formation in epithelial
cells and the cancers derived from them [9,17,34-36].
Germinated brown rice [37], grapes and wine [38] are
nutritional sources rich in GABA and GABA has been
safely used as a nutritional supplement for many years
because of its calming and anxiolytic effects [6]. Unlike
therapy with synthetic GABA receptor agonists, natural
GABA supplementation is virtually without side effects
[6]. In light of the fact that the dose of GABA used in
our animal experiment was within the range of GABA
supplementation used in humans, GABA therapy can
therefore be achieved by a nutritional approach without
the adverse side effects typical for most classic cancer
therapeutics. However, subsets of pancreatic cancers
overexpress the π-subunit of the GABA-A receptor,
converting the cancer inhibiting functions of GABA to
cancer stimulating activity [39]. Individuals with this ab-
normality should therefore be excluded from any attempts
to treat or prevent pancreatic cancer with GABA.
Contrary to GABA, the selective agonist for GABA-B-Rs,
baclofen, failed to reduce nicotine-induced gemcitabine
resistance, did not improve the efficacy of gemcitabine
and did not inhibit the growth of xenografts when used as
single agent treatment. In fact, baclofen alone significantly
increased the levels of cAMP. p-CREB, p-AKT, p-Src and
p-ERK in xenograft tissues while significantly reducing the
levels of cleaved caspase-3. These findings are of concern,
as they suggest that treatment of drug addictions includ-
ing nicotine and alcohol with baclofen [4,5] may promote
the progression of pancreatic cancer while also increasing
gemcitabine resistance. In light of the fact that habitual
ingestion of liquor-strength alcohol and smoking are risk
factors for pancreatic cancer [2,3], individuals undergoing
baclofen therapy for alcohol or nicotine dependence may
harbor precancerous pancreatic lesions that are promoted
to overt cancer by baclofen.
The downregulation of receptor proteins for both
GABA-B receptors observed in xenograft tissues of mice
treated with baclofen in conjunction with the decrease
in xenograft cAMP levels of that treatment group suggest
that the observed adverse effects of baclofen were caused
by agonist-induced downregulation and desensitization of
these receptors. This hypothesis is supported by our
in vitro findings that exposure of BXPC-3 or PANC-1 cells
for seven days to baclofen reduced the protein expression
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ner whereas identical exposures of the cells to GABA did
not change receptor protein. Measurements of intracellu-
lar cAMP additionally showed that pretreatment of cells
for seven days with baclofen completely reversed the
cAMP-inhibiting effects observed after single doses of
baclofen in cells not pretreated with baclofen. These
findings are in accord with the paradoxical superacti-
vation of adenylyl cyclase that has been reported in
response to persistent exposure of Gi-coupled receptors to
agonist concentrations that yielded receptor saturation
[40]. In turn, the resulting increases in xenograft cAMP of
mice treated for 4 weeks with baclofen triggered the
tumor promoting effects of this agent in the current ani-
mal experiment. Identical chronic treatments with GABA
in vivo and in vitro did not trigger desensitization of
GABA-B-Rs and superactivation of adenylyl cyclase be-
cause GABA binds with equal affinity to the large family
of GABA-A receptors that are also expressed in pancreatic
cancer cells [39]. Identical treatments with the GABA-B-R
selective baclofen thus saturated the binding sites of
GABA-B-Rs whereas a significant proportion of the non-
selective GABA bound to GABA-A receptors, resulting in
lower occupancy of GABA-B-R binding sites.
Conclusions
Our data suggest that GABA may have significant thera-
peutic effects on pancreatic cancer when administered as
a single agent and may reduce potential nicotine-induced
gemcitabine resistance. Our data further suggest that
baclofen is contra-indicated in pancreatic cancer pa-
tients because it may induce cancer progression and
increase gemcitabine resistance.
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